Will SGK public coverage with Allianz Sigorta, Anadolu Sigorta, and Acibadem Sigorta employer plans cover this?

Each insurer assesses named-patient imports case by case. Some reimburse fully when Attruby is on their formulary even if not currently stocked, some reimburse a percentage subject to copay, and many require pre-authorisation. We supply the documentation set that allows your insurer to assess the case; the claim itself sits with you or your hospital.

Is the FDA-approved indication recognised by TITCK?

The TITCK named-patient pathway exists precisely to permit access when the local registration or stocking lags the FDA label. The application documents the FDA indication, the reference-authority approval, and the local gap; TITCK review focuses on the clinical justification rather than re-litigating the FDA decision.

My physician is licensed in one emirate / state / province and the hospital is in another. Is that fine?

Any Turkish-licensed physician practicing in good standing in the jurisdiction of the dispensing facility has signing authority on the clinical justification letter. The Turkish Medical Association (TTB) and the Ministry of Health licensing directorate verifies the active license; the TITCK application records both the prescribing physician and the dispensing facility.

Can I receive Attruby at home?

The dispensing facility must be Turkish-licensed. The hospital outpatient or specialty pharmacy releases the medicine to you after final verification, and you then administer or self-administer at home where the FDA label permits, after the dispensing pharmacy's training. The cold-chain or controlled-storage handoff ends at the dispensing pharmacy; home storage and any handling protocol are part of your patient onboarding kit.

What about competitors or alternative therapies in the same class?

Choice of therapy depends on the patient's full phenotype, prior therapy, and the prescriber's judgment. Reserve Meds coordinates whichever medicine the physician has prescribed; we do not substitute, advise on substitution, or promote one brand over another.

Indicative drug-only band: USD 20,000 to 21,000 per month. Delivered quote within 24h.Get my quote

Attruby access in Turkey: the TITCK named-patient pathway

How patients in the Republic of Turkiye legally obtain Attruby (acoramidis) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.

Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.

Quick orientation

Patients in Turkey access Attruby (acoramidis) for transthyretin amyloid cardiomyopathy (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalisation through the TITCK named-patient pathway, a the Turkish Medicines and Medical Devices Agency (Turkiye Ilac ve Tibbi Cihaz Kurumu)-administered mechanism that allows a Turkish-licensed physician at a registered facility to import the FDA-labelled product for a specific named patient. This page details the documentation, approval timeline, and real cost in TRY.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

Reserved for you.

How Attruby reaches patients in Turkey

Attruby (acoramidis, a near-complete TTR stabiliser oral therapy, FDA-approved November 2024 for transthyretin amyloid cardiomyopathy in adults to reduce cardiovascular mortality and cardiovascular-related hospitalisation; marketed by BridgeBio Pharma) is not currently visible on the TITCK registered-product list at titck.gov.tr/dinamikmodul/43 as of 2026-05-31. Turkish patients access Attruby through the Yurt Dışından İlaç Temini named-patient programme under Additional Article 7 of Law No. 1262 and TITCK Kılavuzu Revision 14, accessible at portal.aifd.org.tr TITCK Kılavuzu Rev. 14. The application is filed by the treating cardiologist to the TITCK Commission for Evaluation of Medicines in Personal Treatment. The Attruby-specific clinical justification must document: confirmed ATTR-CM diagnosis by DPD or PYP scintigraphy (Perugini grade 2 or 3) with monoclonal-gammopathy exclusion, or by endomyocardial biopsy with mass-spectrometry typing; TTR genotyping where hATTR is suspected; baseline NYHA class, NT-proBNP, and 6-minute-walk distance; comparison to and rationale for selecting Attruby over tafamidis (Vyndamax) which is locally registered in Turkey and on the SGK formulary (the Attruby case turns on the FDA-label primary endpoint demonstrating reduction in cardiovascular mortality plus cardiovascular-related hospitalisation in ATTRibute-CM, providing a different value proposition than tafamidis). The prescribing cardiologist's TITCK-recognised licence and tertiary-centre affiliation are documented.

Where Attruby is dispensed in Turkey

Attruby is an oral chronic cardiology therapy administered outpatient with cardiac surveillance (echocardiogram, NT-proBNP, NYHA classification, 6-minute walk test). Turkish tertiary cardiology nodes with structured ATTR-CM services include Hacettepe University Faculty of Medicine Department of Cardiology in Ankara at hastane.hacettepe.edu.tr, the longest-standing Turkish amyloidosis reference centre; Ankara University İbni Sina Hospital Department of Cardiology; Istanbul University Çapa Faculty of Medicine Hospital Department of Cardiology in Istanbul; Istanbul University Cerrahpaşa Medical Faculty Hospital Department of Cardiology; Marmara University Pendik Training and Research Hospital Department of Cardiology in Istanbul; Ege University Faculty of Medicine Department of Cardiology in Izmir; Dokuz Eylül University Faculty of Medicine Department of Cardiology in Izmir; Acıbadem Maslak Hospital Department of Cardiology (private tertiary); Anadolu Medical Center Department of Cardiology in Kocaeli; Memorial Şişli Hospital Department of Cardiology; and Medipol Mega University Hospital Department of Cardiology in Istanbul. Hacettepe runs Turkey's inherited-amyloidosis registry and is the most likely Attruby reference centre for both wild-type ATTR-CM (the larger population) and hATTR-CM cases. The DPD scintigraphy capacity for ATTR-CM diagnosis is concentrated at university nuclear-medicine departments.

What Attruby costs in Turkey

The US reference WAC for Attruby is approximately USD 19,000 to USD 20,000 per 30-day supply at the labelled dose of 712 mg twice daily per BridgeBio disclosures and Drugs@FDA at accessdata.fda.gov/scripts/cder/daf. Annual WAC at maintenance dose runs USD 220,000 to USD 240,000. Under the SGK Yurt Dışından İlaç Temini reimbursement framework at sgk.gov.tr, named-patient reimbursement is at the foreign-sourced price exempt from international reference pricing. No public TRY benchmark for Attruby is observed on TITCK or SGK pages as of 2026-05-31 because pricing is set per import transaction. Do not estimate a single TRY figure. Price snapshot: 2026-05-31. TRY/USD spot rate from the Central Bank of Türkiye on the date of any final quote should be footnoted. The locally-registered comparator tafamidis (Vyndamax / Vyndaqel) is on the SGK formulary at a published TRY price; the Attruby economic case requires documented insufficiency of the tafamidis option or a specific clinical preference. Cost layers for SGK-insured patients: drug cost mostly absorbed by SGK; co-payments and administrative fees; TEB or USHAŞ dispensing; and Reserve Meds concierge fee where US-sourced product or expedited timing is preferred.

Funding and access barriers for Attruby in Turkey

ATTR-CM is increasingly recognised in Turkish cardiology following DPD scintigraphy adoption; the ATTR-CM Turkish cohort is growing. Tafamidis (Vyndamax for ATTR-CM monotherapy and Vyndaqel for hATTR polyneuropathy) is locally registered in Turkey and on the SGK formulary for ATTR-CM with documented selection criteria; this is the SGK-default option. The Attruby pathway through Yurt Dışından İlaç Temini requires the prescribing cardiologist to document either insufficiency of tafamidis or the specific value proposition of acoramidis (the ATTRibute-CM trial demonstrated reduction in CV mortality plus CV-related hospitalisation; tafamidis's ATTR-ACT trial demonstrated reduction in all-cause mortality plus CV-related hospitalisation). SGK adjudication on the cross-class switch is case-by-case. For SGK-insured patients (the vast majority), the funding path is structured: TITCK Commission approval, then SGK reimbursement at the foreign-sourced price. Private health insurers (Acıbadem Sigorta, Anadolu Sigorta, AXA Sigorta, Allianz Sigorta, Mapfre Sigorta, Generali, Türk Nippon Sigorta) are supplementary. The İTS drug-tracking-system requirement adds a track-and-trace step for any imported oral capsule. BridgeBio Pharma compassionate-access for ATTR-CM operates case-by-case at early-launch stage in 2026.

Recent regulatory and access news for Attruby

FDA approved Attruby (acoramidis) on 22 November 2024 for ATTR-CM in adults based on the ATTRibute-CM phase 3 trial demonstrating significant reductions in all-cause mortality plus CV-related hospitalisation versus placebo with near-complete TTR stabilisation. The FDA approval letter is at accessdata.fda.gov/scripts/cder/daf. EMA (CHMP) reviewed acoramidis in 2025; EMA EPAR at ema.europa.eu/medicines is the live status page. NICE in England conducted a technology appraisal of acoramidis for ATTR-CM in late 2025 at nice.org.uk. TITCK published Revision 14 of the Yurt Dışından İlaç Temini ve Kullanımı Kılavuzu on 29 August 2024; the İTS regulation per Anadolu Ajansı applies to any acoramidis imports.

Where Reserve Meds fits in Attruby cases

Reserve Meds is a US-based concierge coordinator. We do not replace your treating physician, we do not replace TITCK, and we do not replace your dispensing pharmacy. For Attruby specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it) into Turkey, and assign a single named coordinator through the case. Standard named-patient coordination under our specialty playbook applies. Presentation selection, dose-band confirmation, and patient onboarding for self-administration where applicable are the recurring operational fundamentals we expect for this drug.

Operationally, a typical Attruby case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing plan, monitoring schedule, and the next patient-facing follow-up. The regulatory track is the TITCK application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment with continuous temperature logging and customs broker coordination. The patient-experience track is the named coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks are run in parallel rather than in series; that is the operational difference between a 3-week and a 9-week case.

Turkish specialty care concentrates at the Acibadem, American Hospital, and Memorial chains in Istanbul, with Hacettepe University Hospital in Ankara serving as the principal academic referral centre; the TITCK named-patient supply pathway is routed through the Turkish Pharmacists Association (TEB) foreign medicines channel.

Next step

If your Turkish physician has prescribed Attruby and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.

Start your Attruby case Or message us on WhatsApp